Your Go-To Laboratory CRO to support global COVID-19 Clinical Vaccine Development
With large sample numbers distributed over many locations, a need for expert global logistics support to maintain specimen integrity, quick turnaround time of results and the necessity for globally combinable data, Eurofins Central Laboratory is your go-to partner to support Clinical Vaccine Development.
Since the emergence of the COVID-19 global outbreak, Eurofins Central Laboratory’s clinical testing sites and Kit Packing & Distribution sites have been providing global capacity to deliver critical specimen [self] collection kits and clinical trial testing in support of COVID-19 Clinical Trials.
Eurofins Central Laboratory has over 25 years of experience in Kit Packing and Distribution Services. Eurofins Central Laboratory is a turnkey provider which deploys lean, globally standardized processes, enabling high quality GMP and FDA compliant specimen and transportation kits to be distributed worldwide. Eurofins Central Laboratory uses 3 wholly-owned and managed Kit Packing facilities in Louisville, KY, USA, Oosterhout, the Netherlands and Shanghai, China.
Combining the best of worlds, we integrate our clinical testing global network and global testing portfolio with the Eurofins Vaccines Center of Excellence broad experience to offer one of the broadest capabilities in molecular infectious disease testing, vaccine safety and efficacy assessment, immunogenicity testing, cell-based assays, allergy and hypersensitivity testing, and biomarker analysis.
Further, in collaboration with Eurofins Clinical Trial Supply specialists, Eurofins is able to support visits with Direct-To-Subject Investigational Product distribution as well as Direct- to-Subject study specific specimen collection kits, in coordination with Home Visit Nursing services.
With challenges being experienced worldwide with global supply chains and courier logistics routes, Eurofins is able to provide assistance in both categories. With the significant global volume of courier services utilized annually by Eurofins, we have preferred status with numerous transport companies, allowing prioritization of your specimens.
Viruses are constantly changing, and this includes SARS-CoV-2, the virus that causes COVID-19. These genetic variations occur over time and can lead to the emergence of new variants that may have different characteristics.
At Eurofins, we provide SARS-CoV-2 Variant Sequencing to monitor new emerging variants as some are of particular concern because they spread easier, cause more severe disease, or may escape the body’s immune response.
Eurofins launches COVID-19 PCR tests with at-home self-sampling options in Europe and donates sequencing capacity to identify VUI-2020-12/01 strain reported to spread faster in the UK – December 23, 2020
Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020 – April 28, 2020
Eurofins Genomics U.S. launches new SARS-CoV-2 plasmid DNA controls and increases its capacity to produce probes and primers, all of which being key components of SARS-CoV-2 RT-PCR testing – April 14, 2020
Eurofins Scientific Supports Healthcare Authorities in Europe, the U.S.A. and Brazil in their Fight against the COVID-19 Pandemic with Additional Testing Options and Fast Growing Capacity – March 19, 2020
SARS-CoV-2 is available with a self-pay patient price for those who do not have health insurance or for those who intentionally choose not to submit a claim to their insurance company. SARS-CoV-2 self-pay price is $120. Additional charges may apply for specimen collection, logistics or expedited turnaround testing. This applies to USA only.